Notochordal Cells
Regeneration
Notogen is a biotechnology company focused on treating back and neck dysfunction caused by spinal disc degeneration. Our lead product, NTG-101, is a targeted, non-surgical, non-cellular treatment for degenerative disc disease.
News Release
Nov
2018
18
Notogen Appoints Gary Margolis as New Chief Executive Officer
Nov
2018
13
Therapeutic Potential of NTG-101, a Single Dose Injectable Treatment for Degenerative Disc Disease, Demonstrated in Preclinical Large Animal Study Published in Nature Publishing Group's “Scientific Reports”
Protein-Based, Non-Cellular Biologic
NTG-101 is a patented formulation that protects spinal discs from degeneration, induces disc regeneration, and resolves discogenic pain without the invasiveness and risks associated with surgery or cell therapy.
Preclinical & Commercially Scalable
As a non-cell-based drug candidate, the development of NTG-101 benefits from clearly defined regulatory and manufacturing pathways. It is poised for IND submission and commencement of clinical trials in 2020.